New medicine to treat infections in adults
Vabomere, a combination of an antibiotic and new beta-lactamase inhibitor, addresses bacterial resistance
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vabomere (meropenem trihydrate/vaborbactam), a new treatment option against the following infections in adults:
- Complicated urinary tract infection, including pyelonephritis, a sudden and severe infection causing the kidneys to swell and which may permanently damage them;
- Complicated intra-abdominal infection;
- Hospital-acquired pneumonia, including ventilator associated pneumonia;
- Bacteria in the blood associated with any of the infections listed above;
- Infections due to aerobic Gram-negative organisms in adults with limited treatment options.
The lack of availability of medicines to treat patients with infections caused by resistant bacteria has become a major problem in recent years. It is estimated that at least 25,000 patients in the European Union (EU) die each year from infections due to bacteria that are resistant to many medicines.
Vabomere is a fixed combination of vaborbactam, a new beta-lactamase inhibitor and meropenem, a broad-spectrum antibiotic belonging to the class of carbapenems that is already approved for use in the EU. It is a powder for concentrate for solution for infusion (drip into a vein).
Resistance to carbapenems has been increasing lately, in particular in Gram-negative bacteria, and is of major concern. Beta-lactamases are enzymes involved in bacterial resistance to these antibiotics. By inhibiting the action of beta-lactamases, vaborbactam protects meropenem from being inactivated and restores its activity against many, but not all, carbapenem-resistant pathogens.
In the clinical development program, the exposure to vaborbactam at the recommended dose was shown to be sufficient to protect the activity of meropenem against carbapenem-resistant Enterobacteriaceae. The CHMP also agreed that the studies did not indicate any major concerns regarding the safety profile of meropenem-vaborbactam.
EMA contributes to the European and global effort to tackle antimicrobial resistance. A major area of activity is to create an environment that stimulates and facilitates the development of new antimicrobials. The Agency’s activities also include the monitoring and analysis of data on antimicrobials to guide policy and research, as well as the promotion of their responsible use.
The opinion adopted by the CHMP is an intermediary step on Vabomere’s path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once the marketing authorisations has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.
- The applicant for is Rempex London Ltd.
|New medicine to treat infections in adults||(English only)||21/09/2018|
Latest News from
Regulation on cross border access to e-evidence : Council agrees its position10/12/2018 16:25:00
The EU is taking steps to improve cross-border access to e-evidence by creating a legal framework which will enable judicial orders to be addressed directly to service providers based in another member state.
Council agrees on more effective rules to solve cross border parental responsibility issues10/12/2018 13:25:00
The EU wants to make it easier and faster for decisions on parental responsibility issues and international child abduction to be applied across borders.
Member States and EC to work together to boost artificial intelligence “made in Europe”10/12/2018 12:33:00
This plan proposes joint actions for closer & more efficient cooperation between Member States, Norway, Switzerland and the EC in four key areas: increasing investment, making more data available, fostering talent and ensuring trust.
Migrant smuggling: Council approves a set of measures to fight smuggling networks07/12/2018 15:33:00
The Council has approved a comprehensive & operational set of measures with a law enforcement focus to step up the fight against migrant smuggling networks. This follows a call by EU leaders at their meeting in October
More protection for workers: Council agrees to reduce the exposure to 5 carcinogens07/12/2018 13:25:00
The Council has adopted its position on a proposal which will update the existing rules on the protection of workers from the risks related to exposure to carcinogens or mutagens at work (Directive 2004/37/EC).
Terrorist content online: Council adopts negotiating position on new rules to prevent dissemination07/12/2018 12:37:00
The EU is working to stop terrorists from using the internet to radicalise, recruit and incite to violence. The Council has agreed its negotiating position on the proposed regulation on preventing the dissemination of terrorist content online.
The EU steps up action against disinformation06/12/2018 14:10:00
To protect its democratic systems & public debates and in view of the 2019 European elections as well as a number of national and local elections that will be held in Member States by 2020, the EU has presented an Action Plan to step up efforts to counter disinformation in Europe & beyond.
The EU Budget for 2019: Povisional agreement reached06/12/2018 12:37:00
This agreement is to be confirmed next week during the last plenary session of the European Parliament in Strasbourg.EU funds will continue to be invested in growth & jobs, research & innovation, students & young people – the priorities of the Juncker Commission.
EC calls on Leaders to pave the way for an agreement on a modern, balanced & fair EU budget05/12/2018 16:25:00
Ahead of the European Council meeting on 13 and 14 December 2018, the EC is taking stock of the encouraging progress made so far in the negotiations of the EU's next long-term budget and urging Leaders to keep up the momentum.